Retatrutide 20 + Tirzepatide 40

Retatrutide + Tirzepatide is a multi-agonist research peptide combination designed for laboratory investigation of several incretin and metabolic receptor pathways. Retatrutide is a triple agonist with activity at the glucagon (GCG), glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) receptors, while Tirzepatide acts as a dual GIP and GLP-1 receptor agonist.

This combination may be utilized in controlled laboratory research examining interactions among GLP-1, GIP, and glucagon receptor signaling and related metabolic, glucose-regulatory, and energy-homeostasis pathways.

Contents: Retatrutide 20 mg + Tirzepatide 40 mg Research Classification: Multi-receptor agonist research peptide combination Form: Research peptide combination Intended Use: Laboratory research

Research Use Only. Not for human or veterinary use. This combination has not been established as an approved therapeutic formulation. It is intended solely for qualified laboratory research and analytical applications and is not intended to diagnose, treat, cure, or prevent any disease.